On March 19, 2024, Tempo Therapeutics, a leading innovator in tissue engineering and regenerative medicine, announced the completion of a $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson & Johnson Innovation (JJDC). Wilson Sonsini Goodrich & Rosati has represented Tempo Therapeutics since its inception as a spinout from UCLA and currently represents the company on all legal matters. 

The funding will allow Tempo to advance its Microporous-Annealed-Particle (MAP) technology platform and takes its synthetic tissue scaffold candidates into clinical trials. With this financing, Tempo is entering into the first ever clinical trials of surgical scaffolds based on MAP technology. As the sole developer of MAP technology-based tissue scaffolds, Tempo is poised to reach critical development milestones by establishing the safety and effectiveness of its two lead products: TT101, for complex surgical sites with exposed bone, tendon, or fascia; and TT108 for fascial incision site reinforcement.

The Wilson Sonsini team that advised Tempo Therapeutics on the transaction included:

Patents and Innovations
Matthew Bresnahan
Sara Patak
Brian Brown
Erin Anderson

Corporate
Jason Skolnik
Kassandra Castillo
Leila Purqurian

Technology Transactions
Farah Gerdes
Sarah (Siedlak) Walker
Colin Bosch

For more information, please see Tempo Therapeutics’ press release.